The AAP defines proactive care as an “ evidence-based ” approach based on “intermittent use of anti-inflammatory agents (eg, ...

The presence and severity of atopic dermatitis (AD) in early childhood was not associated with executive dysfunction in ...

L iving with atopic dermatitis can be challenging for anyone, but if someone you love has eczema, it can be particularly tough. About 13 percent of children in the United States have atopic ...

But pediatric atopic dermatitis (eczema) is a common skin condition that affects babies and children. It usually starts between 3 and 6 months and affects about 15% to 20% of children. This type ...

In June 2022 the U.S. Food and Drug Administration (FDA) approved Dupixent to treat moderate-to-severe atopic dermatitis in children 6 months to 5 years old who haven’t achieved enough symptom ...

For the study, investigators evaluated children aged 6 months to 5 years with moderate-to-severe atopic dermatitis who had been treated with either dupilumab or a placebo. Researchers compared ...

Atopic dermatitis (AD) in children is associated with an increased risk for subsequent fracture, according to a research letter published online Nov. 9 in Allergy. Seung Won Lee, M.D., Ph.D., from ...

Moreover, they have explored the impact of vitamin D on allergen sensitization and atopic dermatitis during early childhood. Children with clinically confirmed atopic dermatitis and age-matched ...

Both children and adults with atopic dermatitis have an increased risk of inflammatory bowel disease (IBD), according to a population-based cohort study. In fully adjusted models, kids with atopic ...

Adbry treats atopic dermatitis in adults and some children. The FDA has approved this medicine specifically for the following people: Adults with moderate to severe atopic dermatitis that is not ...

The point prevalence of atopic dermatitis was highest in those aged 0 to 5 years among children and adolescents and in those aged 18 to 59 years among adults. The estimated global point prevalence ...

EBGLYSS is approved for use in adults and children aged 12 years and older, providing a new option for controlling this chronic and debilitating skin condition. Atopic dermatitis is characterized ...